Keeping pace with generative AI in pharmaceutical and healthcare organisations
Increasingly, generative AI is transforming how that information is analysed, summarised and shared. According to 2026 research by the Copyright…
Increasingly, generative AI is transforming how that information is analysed, summarised and shared. According to 2026 research by the Copyright…
“Nothing can ruin your study faster than if your volunteers are not compliant and you can’t retain them.” This was…
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
Every sponsor decision, from dose selection to portfolio prioritisation, depends on whether the evidence generated in a trial is based…
Post-marketing approval studies in clinical research for cancer typically suffer from poor engagement and protracted timelines – driving up costs…
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
For emerging and mid-sized biopharma companies, selecting a drug development partner is now a strategic decision that can determine whether…
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to…
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to…
Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines.…